arsenic trioxide has been researched along with buparlisib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hadden, MK; Wen, J | 1 |
| Bashash, D; Delshad, M; Momeny, M; Pourbagheri-Sigaroodi, A; Riyahi, N; Safaroghli-Azar, A | 1 |
| Alipour, F; Bashash, D; Riyahi, N; Safaroghli-Azar, A; Sari, S; Zandi, Z | 1 |
1 review(s) available for arsenic trioxide and buparlisib
| Article | Year |
|---|---|
Medulloblastoma drugs in development: Current leads, trials and drawbacks.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cerebellar Neoplasms; Humans; Medulloblastoma; Protein Kinase Inhibitors | 2021 |
2 other study(ies) available for arsenic trioxide and buparlisib
| Article | Year |
|---|---|
Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Caspase 3; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Interactions; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Intracellular Space; Leukemia, Promyelocytic, Acute; Morpholines; Phosphatidylinositol 3-Kinases; Reactive Oxygen Species; Signal Transduction | 2018 |
Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO).
Topics: Aminopyridines; Anoikis; Antineoplastic Agents; Arsenic Trioxide; Cell Line; Cell Proliferation; DNA-Binding Proteins; Drug Combinations; Drug Synergism; Epithelial Cells; Female; Forkhead Transcription Factors; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Morpholines; Phosphatidylinositol 3-Kinases; Phosphatidylserines; Signal Transduction; Survivin; Telomerase; Transcription Factors | 2019 |